Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Brandsma

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Cell Stem Cell|September 8, 2021
Antiviral treatment causes a unique mutational signature in cancers of transplantation recipientsJurrian K de Kanter, Flavia Peci, Eline Bertrums, et al.
Cancer Immunology Research|September 27, 2015
Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell KillingArianne M Brandsma, Toine Ten Broeke, Maaike Nederend, et al.
Hemasphere|September 5, 2024
Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypesJurrian K de Kanter, Alexander S Steemers, Daniel Montiel Gonzalez, et al.
Cell Genomics|September 18, 2023
Comprehensive single-cell genome analysis at nucleotide resolution using the PTA Analysis ToolboxSjors Middelkamp, Freek Manders, Flavia Peci, et al.
Cancer Discovery|June 9, 2022
Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid NeoplasmsEline J M Bertrums, Axel K M Rosendahl Huber, Jurrian K de Kanter, et al.
Nature Medicine|June 4, 2013
A functional CFTR assay using primary cystic fibrosis intestinal organoidsJohanna F Dekkers, Caroline L Wiegerinck, Hugo R de Jonge, et al.
Nature Communications|November 19, 2025
Preclinical assessment of two FcγRI-specific antibodies that competitively inhibit immune complex-FcγRI binding to suppress autoimmune responsesTosca Holtrop, Arianne M Brandsma, Louris J Feitsma, et al.
Nature Medicine|March 6, 2019
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapyMeike E W Logtenberg, J H Marco Jansen, Matthijs Raaben, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Cell Stem Cell|September 8, 2021
Antiviral treatment causes a unique mutational signature in cancers of transplantation recipientsJurrian K de Kanter, Flavia Peci, Eline Bertrums, et al.
Cancer Immunology Research|September 27, 2015
Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell KillingArianne M Brandsma, Toine Ten Broeke, Maaike Nederend, et al.
Hemasphere|September 5, 2024
Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypesJurrian K de Kanter, Alexander S Steemers, Daniel Montiel Gonzalez, et al.
Cell Genomics|September 18, 2023
Comprehensive single-cell genome analysis at nucleotide resolution using the PTA Analysis ToolboxSjors Middelkamp, Freek Manders, Flavia Peci, et al.
Cancer Discovery|June 9, 2022
Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid NeoplasmsEline J M Bertrums, Axel K M Rosendahl Huber, Jurrian K de Kanter, et al.
Nature Medicine|June 4, 2013
A functional CFTR assay using primary cystic fibrosis intestinal organoidsJohanna F Dekkers, Caroline L Wiegerinck, Hugo R de Jonge, et al.
Nature Communications|November 19, 2025
Preclinical assessment of two FcγRI-specific antibodies that competitively inhibit immune complex-FcγRI binding to suppress autoimmune responsesTosca Holtrop, Arianne M Brandsma, Louris J Feitsma, et al.
Nature Medicine|March 6, 2019
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapyMeike E W Logtenberg, J H Marco Jansen, Matthijs Raaben, et al.
Pageof 4